Kate Therapeutics (KateTx) focuses on developing adeno-associated virus (AAV)-derived gene therapies targeting specific muscle and heart diseases. This biotechnology company employs innovative technology platforms to overcome the current limitations of gene therapies, such as tissue-specific delivery and gene regulation. These advancements have the potential to enhance the effectiveness and safety of gene therapies, as well as expand the range of treatable conditions that are challenging to address using existing technologies.
Kate Therapeutics
Headquarters
United States of America